Skip to main content
Premium Trial:

Request an Annual Quote

RADx Issues $77.7M in New Contracts for SARS-CoV-2 Rapid Diagnostic Tests

NEW YORK – The National Institutes of Health's Rapid Acceleration of Diagnostics initiative announced on Thursday that it has awarded $77.7 million to develop and manufacture 12 new rapid diagnostic tests for SARS-CoV-2.

The money will be used to support the development, validation, scale-up, and manufacturing of at-home and point-of-care tests, some of which will be brought to market this year, NIH said in a statement.

The companies and organizations receiving grants are: Detect, Palogen, Quidel, Uh-Oh Labs, the University of California, Los Angeles; Becton Dickinson; Ellume; Luminostics; LumiraDx; and Princeton BioMeditech. Five of the grants are for tests detecting viral RNA, and six are for viral antigen detection.

While RADx didn't specify the contract amounts for each company, Detect announced that it received $8.1 million to develop and scale up manufacturing of its Detect COVID-19 Test, an at-home nucleic acid amplification test that provides results in an hour.

The projects are part of the RADx Tech program, which involves an assessment of a test concept conducted by a panel of technical, regulatory, and business experts.

"These technologies represent important innovations to address the need for ready access to rapid, low-costs tests everywhere in the country, including in every home," Bruce Tromberg, director of the National Institute of Biomedical Imaging and Bioengineering and lead for RADx Tech, said in a statement.

"The potential to test simultaneously for multiple types of infection at the point of care is a new frontier that we hope to advance and could be a major step toward transforming US healthcare."

RADx has previously awarded 33 contracts, with 32 projects receiving Emergency Use Authorization from the US Food and Drug Administration.

The RADx funding comes after President Joe Biden announced his COVID-19 Action Plan last month, which emphasized the importance of rapid at-home and POC tests.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.